Blood Res.  2013 Mar;48(1):67-67. 10.5045/br.2013.48.1.67.

Many questions raised by a question on JAK1/2 inhibitors in primary myelofibrosis

• Raut L

• KMID: 2270731
• DOI: http://doi.org/10.5045/br.2013.48.1.67

Abstract

No abstract available.

MeSH Terms

Primary Myelofibrosis

Reference

1. Jung CW. Will JAK1/2 inhibitors change the standard of care for myelofibrosis? Korean J Hematol. 2012; 47:241–242. PMID: 23319999.

2. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366:799–807. PMID: 22375971.